Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
We appreciate the comment from Dr Kobak1 to our previously published report on the clinical course and outcome of COVID-19 in a cohort of patients treated with biologic and targeted synthetic disease modifying antirheumatic drugs.2 The author described the case of a patient with familial Mediterranean fever treated with colchicine who experienced a mild course of COVID-19. Although the effects of colchicine on the clinical course of COVID-19 on large-scale populations are still unknown, colchicine is one of the numerous rheumatologic treatments being tested against severe acute respiratory syndrome coronavirus-2, given its effects on the inflammasome and interleukin and cytokine activation.3 To date, there are at least 11 studies registered on clinicaltrials.gov to test the effects of colchicine on COVID-19. While we await for the results of these trials, the report by Dr Kobak offers further reassuring impressions on the clinical course of COVID-19 in patients treated with various types of antirheumatic agents.
Handling editor Josef S Smolen
Contributors SM and CM contributed equally to the manuscript.
Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.
Competing interests None declared.
Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting or dissemination plans of this research.
Patient consent for publication Not required.
Provenance and peer review Commissioned; internally peer reviewed.